Gut microbiome metabolites in MS inflammation and neurodegeneration

A01

The involvement of nutrition and dietary habits, e.g. the Western diet in MS disease pathogenesis, has only recently become ever more evident. However there is an unmet need for understanding the functional impact of the gut microbiome on disease etiology, pathogenesis, and therapy. We had previously identified fatty acids as metabolites that are linked with the gut associated immune response in the context of MS. In contrast to long chain fatty acids, short chain fatty acids (SCFA) lead to increased differentiation of anti-inflammatory regulatory T cells (Treg), and to a significant amelioration of disease severity in the EAE by daily supplementation with propionic acid (PA). The results of our project clearly indicate that the systemic effect of gut microbiome metabolites on both, immune cells and cells of the enteric/central nervous system, needs to be investigated in more detail. Our main questions are:

    1. Does PA have a direct neuroprotective/neuroregenerative impact? If so, what are the mechanisms?
    2. What are the range of effects of PA on the gut tissue? Are other immune cell subsets affected, i.e. resident myeloid cells?
    3. Does long-term PA supplementation lead to a reversal of MS associated gut microbiome changes (towards healthy controls)?
    4. Which metabolic factors in the gut are altered in response to PA supplementation?

 

 

 

 

 

 

 

 

 

 

 

Principal Investigators:

Univ.-Prof. Dr. med. Aiden Haghikia
Universitätsklinik für Neurologie
Magdeburg
aiden.haghikia@med.ovgu.de

Univ.-Prof. Dr. med. Ralf Gold
Universitätsklinik für Neurologie
Bochum
ralf.gold@rub.de

News

Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more
Wed, 20/01/2021
A new study on neurological manifestations of severe COVID-19 reveals nervous system immune deficiency
Patients suffering from COVID-19 can develop concomitant and long-term symptoms in their nervous system. The most common symptom in this context is the loss of the sense of smell and taste, while more severe symptoms such as stroke, cerebral seizures, or meningitis are possible. A team of scientists from the medical faculties at the Universities […]...more
Fri, 15/01/2021
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
It has long been acknowledged that multiple sclerosis disease risk is associated with reduced sun-exposure, and subsequent low vitamin D levels. The study by Ostkamp et al. now assessed the relationship between measures of sun exposure and MS severity. For this, the researchers analyzed data of around 2,000 patients from the German NationMS- and the […]...more